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ether inhibitors of sulfatases†
Tristan Reuillon, Sari F. Alhasan, Gary S. Beale, Annalisa Bertoli, Alfie Brennan,
Celine Cano, Helen L. Reeves, David R. Newell, Bernard T. Golding,* Duncan C. Miller*
and Roger J. Griffin‡
Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecules
targeting this enzyme has proved challenging. Based on molecular modelling, two series of sulfatase-2
inhibitors have been developed with biphenyl and biphenyl ether scaffolds judiciously substituted with
sulfamate, carboxylate and other polar groups (e.g. amino). Inhibition of aryl sulfatase A and B was also
determined. The biphenyl ether derivatives were less selective for sulfatase-2 over aryl sulfatase B than
the biphenyl series. All biphenyl ether derivatives inhibited aryl sulfatase A, whereas only amino
derivatives inhibited aryl sulfatase B significantly. In the biphenyl series few derivatives exhibited activity
against aryl sulfatase B. The trichloroethylsulfamate group was identified as a new pharmacophore
enabling potent inhibition of all of the sulfatases studied.Introduction
Sulfatase-1 (Sulf-1) and sulfatase-2 (Sulf-2) catalyse the hydro-
lysis of the 6-O-sulfate group attached to glucosamine residues
in heparan sulfate proteoglycans (HSPGs).1 The HSPG
substrates consist of a protein core linked to heparan sulfate
polysaccharide chains derived from repeating disaccharide
units comprising a hexuronic acid (glucuronic acid or iduronic
acid) and glucosamine. Removal of the 6-O-sulfate affects the
mobilisation of heparan bound growth factors and cytokines,2
including broblast growth factor (FGF) and wingless-related
integration site (wnt).3 The role of FGF in cell proliferation,
invasion, migration and angiogenesis,4 and of wnt in cell
growth and proliferation,5 implicate the sulfatases as potential
targets for therapeutic intervention in certain diseases
including pulmonary brosis6 and prostate,7 colorectal,8
ovarian, and breast cancers.9 Very few small molecule inhibitors
of Sulf-1 and Sulf-2 have been reported.10,11 On re-synthesis, the
purported activity against Sulf-2 of a group of monosaccharide
sulfamate-based inhibitors could not be replicated.12 The
nitrone ‘OKN-007’ is a suboptimal Sulf-2 inhibitor tool
compound, having several proposed potential chemical and
biological mechanisms of action in addition to Sulf-2 inhibi-
tion, including suppression of NO production, S-nitrosylation offor Cancer Research, School of Chemistry,
castle Upon Tyne, NE1 7RU, UK. E-mail:
.miller@ncl.ac.uk; Fax: +44 (0)191
tion (ESI) available. See DOI:
Chemistry 2016critical proteins and inhibition of NF-kB activation.13 The diffi-
culty in identifying small molecule inhibitors of Sulf-2 has led to
the investigation of indirect methods to affect Sulf-2 through
inhibition of the proteosomal machinery.14 However, in this
paper we report new saccharide mimics that inhibit Sulf-2
directly. We have also identied the trichloroethylsulfamate
group as a new pharmacophore for Sulf-2 inhibition. Among the
compounds described are the rst relatively potent small
molecule inhibitors of Sulf-2 that will aid further biological
studies and assist elucidation of the role of Sulf-2 in cancer.De novo inhibitor design
There is no crystal structure for Sulf-2 and a lack of either small
molecule inhibitors or biological assay suitable for a high-
throughput screening campaign. Given these constraints, the
structure of heparan sulfate proteoglycans, which are the
endogenous ligands of Sulf-2, was used as a template for the
design of potential Sulf-2 inhibitors. With no solved structures
of a HSPG, the principal structural motifs of HSPG reported to
be substrates for Sulf-2 are the highly sulfated regions, which
closely resemble heparin in structure.15 However, structures of
heparin in solution have been solved by NMR (pdb code
1hpn).16 These were compared with structures of heparin bound
to protein partners such as the NK1 growth factor (pdb code
1gmn), 3-O-sulfotransferase (pdb code 1t8u) and heparin lyase
(pdb code 3ina). The bound form was found to resemble the
solution a-helical form, with interactions to protein binding
partners being dominated by contacts between the sulfate and
carboxylate functionalities on the surface of the heparin helix.
Negatively charged sulfate and carboxylate groups cover most ofChem. Sci.
Fig. 2 Representative overlays of biphenyl ethers (cyan) with
a heparin-derived trisaccharide template (green).
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View Article Onlinethe accessible surface of the heparin polymer, and have been
shown to regulate the binding of heparin to the enzyme 3-O-
sulfotransferase.16,17 X-ray crystal structures of FGF-1 and FGF-2
in complex with heparin oligosaccharides also revealed the
importance of the sulfate and carboxylate groups for binding.18
These studies demonstrated that interactions of the charged
sulfate and carboxylate groups on the heparin oligosaccharide
with basic amino acids on protein binding partners are the
main contributors to tight and specic binding. Mimicking
these ionic interactions was a key consideration for de novo
design of potential non-saccharide based Sulf-2 inhibitors.
Potential sulfamate inhibitors were designed with the aim of
identifying hit compounds with improved Sulf-2 inhibition and
physicochemical properties compared to the mono-
saccharides.12 The arylsulfamate group has been shown to be
a privileged structure for the inhibition of sulfatases,19 although
much of this work was focused on steroid sulfatase (STS).
Potential Sulf-2 inhibitors were designed initially by overlaying
a primary phenylsulfamate (A-ring) with the 6-O sulfate of
glucosamine of a representative trisaccharide taken from the
reducing end of the heparin solution structure (1hpn). Vectors
where the phenyl ring could be substituted to allow incorpora-
tion of a second polar group that could overlay a surface polar
group on the heparin helix were explored. Compounds from
both biphenyl (Fig. 1) and biphenyl ether sulfamate (Fig. 2)
series were energy minimised and found to enable such
a superposition of polar functionality. A primary sulfamate
group at the 3-position of the (A-ring) in the biphenyl series
enabled substituents on the second phenyl ring to overlay the N-
sulfate of glucosamine or the O-sulfate of iduronic acid in the
template structure. In addition to these rationally designed
derivatives, the biphenyl core was used to probe additional
polar and ionic interactions through incorporation of polar
functional groups at the ortho,meta and para positions of the B-
ring. In the biphenyl ether sulfamate scaffold the oxygen linker
allows different conformations with alternative positioning of
groups on the B-ring relative to the A-ring.Fig. 1 Representative overlays of biphenyl targets (cyan) with
a heparin-derived trisaccharide template (green) created using the
proprietary structural visualisation program MoViT (Pfizer).
Chem. Sci.Synthesis of inhibitors
A number of highly efficient synthetic routes were implemented
that should have wide applicability for sulfamate synthesis. Key
to the synthesis of the desired templates was our previously
reported sulfamate protecting group methodology using the N-
2,4-dimethoxybenzyl (dmb) group,20 which was applied to the
synthesis of libraries of biphenyl- and biaryl ether-sulfamates.
Microwave-assisted Suzuki–Miyaura cross-coupling of 1 in the
presence of potassium carbonate and Pd(PPh3)4 afforded 2 in
75% yield (method i, Scheme 1 and Table 1). Alternative Suzuki
conditions (method ii, Scheme 1 and Table 1) were required for
the preparation of 3–7. All deprotections proceeded at room
temperature in dilute TFA, resulting in high yields of the
desired primary sulfamates 8–13.
The preparation of amino-substituted biaryl ether-sulfa-
mates 25–27 started from resorcinol 16 (Scheme 2 and Table 2).
The use of high dilution (0.08 M) and low temperature pre-
vented side-reactions during the methylation/imidazolium
displacement step. SNAr reaction of uoronitrobenzenes with
18 gave biphenyl ether intermediates 19–21, which were
reduced via palladium-catalysed ow hydrogenation. Depro-
tection of 22–24 gave high yields of the desired primary sulfa-
mates 25–27.
Methyl ester 2 was hydrolysed under basic conditions and
the resulting carboxylic acid 14 was deprotected to give 15
(Scheme 3 and Table 3). Acetylation of aniline derivatives 5–7
and 22–24 afforded acetamidobiphenyls 28–33, which were
deprotected to give 34–39.
Attempted preparation of the 20-sulfamic acid derivative by
reaction of aniline 5 with sulfur trioxide-pyridine complex was
unsuccessful. Taylor et al. reported the 2,2,2-trichloroethyl
(TCE) group as an effective protecting group for arylsulfate
esters21 and this methodology was adapted to the synthesis ofScheme 1 Synthesis of biphenyl sulfamates 8–13. Reagents and
conditions: (i) K2CO3, RC6H4B(OH)2, Pd(PPh3)4, MeCN, 120 C, mW, 20
min; (ii) RC6H4B(pin), 2 M aq. Na2CO3, Pd(dppf)Cl2, dioxane, 80 C, mW,
20 min; (iii) 10% TFA/DCM, RT, 2 h.
This journal is © The Royal Society of Chemistry 2016
Table 1 Summary of yields for synthesis of biphenyl sulfamates
R
Step 1 Step 2
Method Yield Yield
2-CO2Me i 2 75% 8 88%
3-CO2H ii 3 79% 9 82%
4-CO2H ii 4 77% 10 90%
2-NH2 ii 5 82% 11 83%
3-NH2 ii 6 77% 12 82%
4-NH2 ii 7 72% 13 82%
Scheme 2 Synthesis of biaryl ether-sulfamates 25–27. Reagents and
conditions: (i) 1,10-sulfonylbis(2-methyl-1H-imidazole), Cs2CO3,
MeCN, 120 C, mW, 15 min, 80%; (ii) (a) Me3O$BF4, DCM : THF (8 : 1),
0 C to RT, 9 h; (b) bis(2,4-dimethoxy benzyl)amine, MeCN, 42 C, 24
h, 60%; (iii) fluoronitrobenzene, K2CO3, DMF, 150 C, mW, 20 min; (iv)
H2, 10% Pd/C, MeOH : THF (3 : 1), RT, 24 h; (v) 10% TFA/DCM, RT, 2 h.
Table 2 Summary of yields for synthesis of biaryl ether-sulfamates
Position Step 3 Step 4 Step 5
20- 19 80% 22 85% 25 90%
30- 20 75% 23 87% 26 82%
40- 21 85% 24 86% 27 65%
Table 3 Summary of yields for functionalisation/deprotection of
protected biphenyl sulfamates
R R0 n
Step 1 Step 2
Method Yield Yield
2-CO2Me 2-CO2H 0 i 14 80% 15 89%
2-NH2 2-NHAc 0 ii 28 87% 34 86%
3-NH2 3-NHAc 0 ii 29 89% 35 91%
4-NH2 4-NHAc 0 ii 30 88% 36 84%
2-NH2 2-NHAc 1 ii 31 87% 37 85%
3-NH2 3-NHAc 1 ii 32 88% 38 94%
4-NH2 4-NHAc 1 ii 33 86% 39 92%
Scheme 4 Synthesis of 2,3-dimethyl-1-((2,2,2-trichloroethoxy)-
sulfonyl)-1H-imidazol-3-ium tetrafluoroborate 44. Reagents and
conditions: (i) SO2Cl2, pyridine, Et2O, 78 C, 4 h, 83%; (ii) 2-methyl-
imidazole, THF, 0 C to RT, 16 h, 95%; (iii) Me3O$BF4, DCM, 0 C to RT,
20 h, 86%.
Scheme 5 Synthesis of amino-sulfate derivatives 54–57. Reagents
and conditions: (i) 44, MeCN, 120 C, mW, 20 min; (ii) 10% TFA/DCM,
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View Article Onlineprotected sulfamic acids. TCE chlorosulfate 42 was obtained by
reacting sulfuryl chloride with one equivalent of 2,2,2-tri-
chloroethanol 41 (Scheme 4). Reaction of 42 with 2-methyl-
imidazole gave 2-methylimidazole-1-sulfonate 43, which was
methylated with Meerwein's salt to give 44.Scheme 3 Functionalisation/deprotection of protected biphenyl sul-
famates. Reagents and conditions: (i) LiOH, H2O/THF, 60 C, 24 h,
80%; (ii) Ac2O, NEt3, DCM, RT, 24 h; (iii) 10% TFA/DCM, RT, 2 h.
This journal is © The Royal Society of Chemistry 2016Reacting the appropriate anilines with 3 molar equivalents
of 44 under microwave irradiation in acetonitrile at 120 C for
20 min afforded the meta- (45 and 48) and para- (46 and 49)RT, 2 h; (iii) (a) Zn powder, MeOH, acetate buffer pH 4.65, 60 C, 2 h; (b)
Dowex 50W8X2 Na+ form, H2O.
Table 4 Summary of yields for the synthesis of amino-sulfate
derivatives
Position n Step 1 Step 2 Step 3
20- 0 40 0% — —
30- 0 45 75% 50 86% 54 84%
40- 0 46 82% 51 91% 55 80%
20- 1 47 15% — —
30- 1 48 78% 52 86% 56 75%
40- 1 49 90% 53 89% 57 70%
Chem. Sci.
Table 6 Monosubstituted phenyl and biphenyl derivatives
Cmpd R X R0
76 Ph O NH2
77 Ph O NMe2
78 OPh O NH2
79 Ph NH OCH2CCl3
80 OPh NH OCH2CCl3
81 Ph O OCH2CCl3
82 Ph NH OCH2CF3
83 H NH OCH2CCl3
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 1
1/
03
/2
01
6 
12
:1
0:
03
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinederivatives, but poor conversion was observed with ortho-
anilines 5 and 22 (Scheme 5 and Table 4). The trichloroethyl
group was stable under the acidic conditions used for sulfamate
deprotection. Cleavage of the trichloroethyl group was achieved
using zinc in a mixture of methanol and acetate buffer with no
desulfamoylation. The resulting sulfamic acids were converted
to sodium salts using ion exchange chromatography, affording
targets 54–57 in high yields.
Protection of 2-aminobiphenyls 5 and 22 with TCE chlor-
osulfate 44 produced bis-N,N-sulfated aminobiphenyls 58 and
59, respectively (Scheme 6), which were deprotected to afford 60
and 61. A one-pot deprotection/mono-sulfate hydrolysis of 60
and 61 led to the isolation of 62 and 63.
SNAr reactions with uorobenzonitriles 64–66 gave cyanobi-
phenyl ethers 67–69 which were hydrolysed to the correspond-
ing benzoic acids 70–72 (Scheme 7 and Table 5). Acidic
deprotection of the sulfamate moiety afforded targets 73–75.
Thus, sets of substituted biphenyl and biphenyl ether sulfa-
mates were prepared. Compounds 76–82 (Table 6) bearingScheme 6 Synthesis of amino-sulfate derivatives 62, 63. Reagents and
conditions: (i) 44, NEt3, DMAP, THF, 0 C to RT, 24 h, n ¼ 0 70%, n ¼ 1
55%; (ii) 10% TFA/DCM, RT, 2 h, n ¼ 0 90%, n ¼ 1 86%; (iii) Zn powder,
MeOH, acetate buffer pH 4.65, AcOH, RT, 24 h; Dowex 50W8X2 Na+
form, H2O, n ¼ 0 50%, n ¼ 1 33%.
Scheme 7 Synthesis of benzoic acid derivatives 73–75. Reagents and
conditions: (i) 18, K2CO3, DMF, 150 C, mW, 20 min; (ii) 2 M aq. NaOH,
dioxane, 130 C, mW, 2 h; (iii) 10% TFA/DCM, RT, 2 h.
Table 5 Summary of yields for synthesis of benzoic acid derivatives
Position Step 1 Step 2 Step 3
20- 67 81% 70 45% 73 90%
30- 68 61% 71 80% 74 94%
40- 69 72% 72 65% 75 92%
Chem. Sci.a single substituent on the aromatic core were also prepared by
analogous routes (see ESI data†).Biological evaluation
Compounds were assayed for their ability to inhibit the Sulf-2-
catalysed desulfation of 4-methylumbelliferyl sulfate (4-MUS) to
the uorescent 4-methylumbelliferone (MU). To determine
their sulfatase selectivity, inhibition of aryl sulfatases A (ARSA)
and B (ARSB) was also assessed. To date no suitable benchmark
inhibitors of these sulfatase have been reported. In the biphenyl
series (Table 7A), only the trichloroethylsulfamates (50 and 51)
exhibited high Sulf-2 inhibition giving almost complete inhi-
bition of sulfatase activity at 1 mM concentration. The position
and nature of the substituent on the B ring had a pronounced
effect on the sulfatase inhibition. In the majority of cases the
presence of a substituent on the B-ring was detrimental to Sulf-2
inhibition when compared with unsubstituted biphenyl sulfa-
mate 76. Aminosulfates 54 and 62 and carboxylic acid 15
retained potency. Surprisingly, the synthetic tri-
chloroethylsulfamate intermediates 50 and 51 exhibited potent
inhibition. Compounds 8, 10, 15, 50 and 51 were also relatively
potent ARSA inhibitors. The tertiary dimethylsulfamate 77
exhibited no Sulf-2 inhibition (0% inh @ 1 mM). Similar SAR
was observed with the 3-phenoxyphenyl template (Table 7B)
with the trichloroethylsulfamates 52 and 53 again proving to be
superior inhibitors against all sulfatases tested. Aminosulfates
56 and 63 were the best Sulf-2 inhibitors lacking a tri-
chloroethylsulfamate group. In summary, the design strategy of
introducing polar groups to mimic polar groups of the endog-
enous substrate did not give the anticipated improvement in
Sulf-2 inhibition, whereas the presence of a relatively large,
lipophilic trichloroethylsulfamate group on the B-ring in both
templates provided superior inhibitors.
To understand the origin of sulfatase inhibition by
compounds 50–53, compounds 79 and 80, lacking a primary
sulfamate, were prepared and found to be also potent Sulf-2
inhibitors (Table 8), indicating that the primary sulfamate
group is not essential for sulfatase inhibition with these
templates. Compound 79 exhibited some selectivity over ARSAThis journal is © The Royal Society of Chemistry 2016
Table 9 Sulfatase IC50 data for inhibitors 50–51, 53, 79–80. IC50
values were calculated using non-linear regression analysis for 7
different inhibitor concentrations each performed in duplicate to give
the mean  SEM
Compound Sulf-2 IC50 (mM) ARSA IC50 (mM) ARSB IC50 (mM)
50 167  5 55  11 130  6
51 566  28 91  4 101  8
53 390  11 108  2 116  10
79 254  3 No inhibition 30  11
80 298  3 nd 34  9
Table 8 Sulfatase inhibition data for analogues lacking a primary
sulfamate group. Data are means of two or more determinations
Cpd R X R0
Sulf-2%
inh @ 1 mM
ARSA%
inh @ 1 mM
ARSB%
inh @ 1 mM
83 H NH CH2CCl3 3 63 68
79 Ph NH CH2CCl3 100 0 61
80 OPh NH CH2CCl3 99 74 99
81 Ph O CH2CCl3 1 70 85
82 Ph NH CH2CF3 5 78 92
Table 7 Sulfatase inhibition data for biphenylsulfamates. Data are
means of two or more determinations. n.d. ¼ not determined
Cpd R
Sulf-2%
inh @ 1 mM
ARSA%
inh @ 1 mM
ARSB%
inh @ 1 mM
A: n ¼ 0
76 H 38 14 65
8 20-CO2Me 20 86 0
15 20-CO2H 31 98 0
9 30-CO2H 12 59 0
10 40-CO2H 22 85 0
11 20-NH2 21 0 0
12 30-NH2 20 0 0
13 40-NH2 6 61 0
34 20-NHAc 4 33 0
35 30-NHAc 8 52 33
36 40-NHAc 3 0 0
62 20-NHSO3Na 37 26 0
54 30-NHSO3Na 31 0 0
55 40-NHSO3Na 4 0 0
60 20-N(SO3CH2CCl3)2 10 63 0
50 30-NHSO3CH2CCl3 99 92 67
51 40-NHSO3CH2CCl3 96 99 68
B: n ¼ 1
78 H 32 n.d. n.d.
73 20-CO2H 10 44 0
74 30-CO2H 30 49 0
75 40-CO2H 23 33 0
25 20-NH2 28 75 17
26 30-NH2 31 75 0
27 40-NH2 14 75 0
37 20-NHAc 11 29 48
38 30-NHAc 10 57 0
39 40-NHAc 14 45 0
63 20-NHSO3Na 56 54 93
56 30-NHSO3Na 58 95 85
57 40-NHSO3Na 13 34 77
61 20-N(SO3CH2CCl3)2 18 82 40
52 30-NHSO3CH2CCl3 100 100 96
53 40-NHSO3CH2CCl3 98 96 86
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineand ARSB, whereas compound 80 was a good inhibitor for all of
the sulfatases. Compound 83, the simple phenyl tri-
chloroethylsulfamate derivative did not retain Sulf-2 inhibitory
activity, suggesting that the trichloroethylsulfamate group is
not sufficient per se to impart sulfatase inhibition and is not
conferring pan-sulfatase activity through a non-specic mech-
anism of action. Compound 83 did, however, possess inhibitory
activity against both ARSA and ARSB. Trichloroethylsulfate 81
and triuoroethylsulfamate 82 exhibited no Sulf-2 inhibition,
but retained activity against ARSA and ARSB. Thus, it appears
that the trichloroethylsulfamate group is a new motif for Sulf-2
inhibition, and that, in combination with lipophilic groups,
inhibitors of Sulf-2 lacking a primary sulfamate moiety can be
developed.
Sulf-2 IC50 values were determined for the most potent
inhibitors (Table 9). Compound 50 had the highest Sulf-2
inhibitory activity with an IC50 value of 167 mM. The ARSA and
ARSB inhibitory activity of all compounds tested proved to be
higher than their Sulf-2 inhibitory activity, providing the rst
reported inhibitors of ARSA and ARSB with IC50 < 1 mM.
Following screening at 1 mM, ARSA inhibition by 80 was eval-
uated over the concentration range 0.025–1mM. Concentration-
dependent inhibition was not observed and hence an IC50 value
could not be determined. Aryl sulfamate-based inhibitors of
steroid sulfatase have demonstrated irreversible inhibition
proles.15 Further studies will be required to determine if the
aryl sulfamates such as 50, and trichloroethylsulfamates such
as 80 behave as irreversible sulfatase inhibitors.Conclusions
Two new series of sulfatase inhibitors have been developed
based on biphenyl and biphenyl ether templates, with highly
effective synthetic procedures providing access to a variety of
sulfamates and aminosulfates. The trichloroethylsulfamates
50–53, 79 and 80 exhibited favourable Sulf-2 inhibition. The
trichloroethylsulfamate group has therefore been identied as
a new pharmacophore for sulfatase inhibition. Further studies
will be required to determine the origin of sulfatase inhibition
by aryl trichloroethylsulfamates. The most potent Sulf-2 inhib-
itors lacking a trichloroethylsulfamate group were biphenyl
ether aminosulfates 56 and 63. The diphenyl ether derivatives
also proved to be moderate to good inhibitors of ARSA, whereas
signicant inhibition of ARSB was only observed withChem. Sci.
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View Article Onlinesubstituted amino derivatives. This trend was not retained in
the biphenyl series with few derivatives exhibiting activity
against ARSB. However, the rst inhibitors of ARSA and ARSB
with IC50 < 1 mM are reported. Additional SAR studies are
underway to improve Sulf-2 potency and to delineate the factors
affecting selectivity.
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